<DOC>
	<DOCNO>NCT01615978</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial ass safety multiple s.c. ( subcutaneously ) dose liraglutide Japanese subject type 2 diabetes .</brief_summary>
	<brief_title>Safety Tolerability Liraglutide Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Duration diabetes 12 week Subjects currently diet therapy ( OHAna√Øve ) treat OHA ( oral hypoglycaemic agent ) monotherapy 12 week HbA1c ( Glycated haemoglobin A1c ) 6.09.0 % , inclusive Body Mass Index ( BMI ) : 18.530.0 kg/m^2 Recurrent severe hypoglycaemia Proliferative retinopathy maculopathy require acute treatment Impaired hepatic function Impaired renal function Cardiac problem Uncontrolled treated/untreated hypertension Current treatment insulin preparation TZDs ( thiazolidinediones ) Current treatment expect screening start treatment systemic corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>